Overview

The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-10-30

Target enrollment:

Participant gender:

Summary

This study is a prospective, single-arm, open-label exploratory clinical study conducted in subjects with ANCA-associated nephritis (AAGN), aiming to evaluate the efficacy and safety of Telitacicept in the treatment of AAGN.

Phase:

PHASE1

Details

Lead Sponsor:

Renmin Hospital of Wuhan University

Treatments:

Cyclophosphamide
Methylprednisolone
Prednisone
telitacicept